Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD

Biochemical and Biophysical Research Communications

Volumn 412, Issue 2, 2011, Pages 307-312

  Razumovskaya, Elena ^a   Sun, Jianmin ^a   Rönnstrand, Lars ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Acute myeloid leukemia; Apoptosis; ERK5; FLT3; MEK5; Proliferation; Receptor tyrosine kinase

Indexed keywords

BIX 02188; CD135 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TANDEM REPEAT; WILD TYPE;

ANILINE COMPOUNDS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; LEUKEMIA; LIGANDS; MAP KINASE KINASE 5; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 7; ONCOGENE PROTEINS; PHOSPHORYLATION;

EID: 80052025517     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.089     Document Type: Article

References (45)

1. Maroc N., Rottapel R., Rosnet O., Marchetto S., Lavezzi C., Mannoni P., Birnbaum D., Dubreuil P. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene 1993, 8:909-918.
2. Turner A.M., Lin N.L., Issarachai S., Lyman S.D., Broudy V.C. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996, 88:3383-3390.
3. Rosnet O., Bühring H.J., deLapeyriere O., Beslu N., Lavagna C., Marchetto S., Rappold I., Drexler H.G., Birg F., Rottapel R., Hannum C., Dubreuil P., Birnbaum D. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol. 1996, 95:218-223.
4. Kiyoi H., Towatari M., Yokota S., Hamaguchi M., Ohno R., Saito H., Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998, 12:1333-1337.
5. Kiyoi H., Ohno R., Ueda R., Saito H., Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002, 21:2555-2563.
6. Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F., Lippke J., Saxena K. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 2004, 13:169-178.
7. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
8. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
9. Scheijen B., Griffin J.D. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002, 21:3314-3333.
10. Zhou G., Bao Z.Q., Dixon J.E. Components of a new human protein kinase signal transduction pathway. J. Biol. Chem. 1995, 270:12665-12669.
11. Nishimoto S., Nishida E. MAPK signalling: ERK5 versus ERK1/2. EMBO Rep. 2006, 7:782-786.
12. Wang X., Tournier C. Regulation of cellular functions by the ERK5 signalling pathway. Cell. Signal. 2006, 18:753-760.
13. Buschbeck M., Ullrich A. The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling. J. Biol. Chem. 2005, 280:2659-2667.
14. Kato Y., Kravchenko V.V., Tapping R.I., Han J., Ulevitch R.J., Lee J.D. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 1997, 16:7054-7066.
15. Yan C., Luo H., Lee J.D., Abe J., Berk B.C. Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains. J. Biol. Chem. 2001, 276:10870-10878.
16. Morimoto H., Kondoh K., Nishimoto S., Terasawa K., Nishida E. Activation of a C-terminal transcriptional activation domain of ERK5 by autophosphorylation. J. Biol. Chem. 2007, 282:35449-35456.
17. Abe J., Kusuhara M., Ulevitch R.J., Berk B.C., Lee J.D. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J. Biol. Chem. 1996, 271:16586-16590.
18. Kato Y., Tapping R.I., Huang S., Watson M.H., Ulevitch R.J., Lee J.D. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998, 395:713-716.
19. Kamakura S., Moriguchi T., Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem. 1999, 274:26563-26571.
20. Watson F.L., Heerssen H.M., Bhattacharyya A., Klesse L., Lin M.Z., Segal R.A. Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. Nat. Neurosci. 2001, 4:981-988.
21. Obara Y., Yamauchi A., Takehara S., Nemoto W., Takahashi M., Stork P.J., Nakahata N. ERK5 activity is required for nerve growth factor-induced neurite outgrowth and stabilization of tyrosine hydroxylase in PC12 cells. J. Biol. Chem. 2009, 284:23564-23573.
22. Izawa Y., Yoshizumi M., Ishizawa K., Fujita Y., Kondo S., Kagami S., Kawazoe K., Tsuchiya K., Tomita S., Tamaki T. Big mitogen-activated protein kinase 1 (BMK1)/extracellular signal regulated kinase 5 (ERK5) is involved in platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell migration. Hypertens. Res. 2007, 30:1107-1117.
23. Rovida E., Navari N., Caligiuri A., Dello Sbarba P., Marra F. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. J. Hepatol. 2008, 48:107-115.
24. Lennartsson J., Burovic F., Witek B., Jurek A., Heldin C.H. Erk 5 is necessary for sustained PDGF-induced Akt phosphorylation and inhibition of apoptosis. Cell Signal 2010, 22:955-960.
25. Mody N., Campbell D.G., Morrice N., Peggie M., Cohen P. An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. Biochem. J. 2003, 372:567-575.
26. Cavanaugh J.E. Role of extracellular signal regulated kinase 5 in neuronal survival. Eur. J. Biochem. 2004, 271:2056-2059.
27. Finegan K.G., Wang X., Lee E.J., Robinson A.C., Tournier C. Regulation of neuronal survival by the extracellular signal-regulated protein kinase 5. Cell Death Differ. 2009, 16:674-683.
28. Wang X., Finegan K.G., Robinson A.C., Knowles L., Khosravi-Far R., Hinchliffe K.A., Boot-Handford R.P., Tournier C. Activation of extracellular signal-regulated protein kinase 5 downregulates FasL upon osmotic stress. Cell Death Differ. 2006, 13:2099-2108.
29. Tatake R.J., O'Neill M.M., Kennedy C.A., Wayne A.L., Jakes S., Wu D., Kugler S.Z., Kashem M.A., Kaplita P., Snow R.J. Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem. Biophys. Res. Commun. 2008, 377:120-125.
30. Heiss E., Masson K., Sundberg C., Pedersen M., Sun J., Bengtsson S., Rönnstrand L. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood 2006, 108:1542-1550.
31. Voytyuk O., Lennartsson J., Mogi A., Caruana G., Courtneidge S., Ashman L.K., Rönnstrand L. Src family kinases are involved in the differential signaling from two splice forms of c-Kit. J. Biol. Chem. 2003, 278:9159-9166.
32. Pedersen M., Rönnstrand L., Sun J. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. Cell. Signal. 2009, 21:413-418.
33. Lennartsson J., Burovic F., Witek B., Jurek A., Heldin C.H. Erk 5 is necessary for sustained PDGF-induced Akt phosphorylation and inhibition of apoptosis. Cell. Signal. 2010, 22:955-960.
34. Roberts O.L., Holmes K., Müller J., Cross D.A., Cross M.J. ERK5 is required for VEGF-mediated survival and tubular morphogenesis of primary human microvascular endothelial cells. J. Cell Sci. 2010, 123:3189-3200.
35. Blume-Jensen P., Janknecht R., Hunter T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 1998, 8:779-782.
36. Möller C., Alfredsson J., Engström M., Wootz H., Xiang Z., Lennartsson J., Jönsson J.I., Nilsson G. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 2005, 106:1330-1336.
37. Levis M., Allebach J., Tse K.F., Zheng R., Baldwin B.R., Smith B.D., Jones-Bolin S., Ruggeri B., Dionne C., Small D. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002, 99:3885-3891.
38. Quentmeier H., Reinhardt J., Zaborski M., Drexler H.G. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003, 17:120-124.
39. Schmidt-Arras D., Böhmer S.A., Koch S., Müller J.P., Blei L., Cornils H., Bauer R., Korasikha S., Thiede C., Böhmer F.D. Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Blood 2009, 113:3568-3576.
40. Zheng R., Bailey E., Nguyen B., Yang X., Piloto O., Levis M., Small D. Further activation of FLT3 mutants by FLT3 ligand. Oncogene 2011.
41. Sticht C., Freier K., Knöpfle K., Flechtenmacher C., Pungs S., Hofele C., Hahn M., Joos S., Lichter P. Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). Neoplasia 2008, 10:462-470.
42. Garaude J., Cherni S., Kaminski S., Delepine E., Chable-Bessia C., Benkirane M., Borges J., Pandiella A., Iniguez M.A., Fresno M., Hipskind R.A., Villalba M. ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J. Immunol. 2006, 177:7607-7617.
43. Yang Q., Deng X., Lu B., Cameron M., Fearns C., Patricelli M.P., Yates J.R., Gray N.S., Lee J.D. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 2010, 18:258-267.
44. Grundler R., Thiede C., Miething C., Steudel C., Peschel C., Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003, 102:646-651.
45. Bagrintseva K., Schwab R., Kohl T.M., Schnittger S., Eichenlaub S., Ellwart J.W., Hiddemann W., Spiekermann K. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 2004, 103:2266-2275.